171 related articles for article (PubMed ID: 19693537)
41. Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.
Tian A; Wilson GS; Lie S; Wu G; Hu Z; Hebbard L; Duan W; George J; Qiao L
Cancer Lett; 2014 Sep; 351(2):232-41. PubMed ID: 24976294
[TBL] [Abstract][Full Text] [Related]
42. Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma.
He X; Li J; Guo W; Liu W; Yu J; Song W; Dong L; Wang F; Yu S; Zheng Y; Chen S; Kong Y; Liu C
Oncotarget; 2015 Feb; 6(4):2302-14. PubMed ID: 25544773
[TBL] [Abstract][Full Text] [Related]
43. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
44. Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma.
Xia J; Rong L; Sawakami T; Inagaki Y; Song P; Hasegawa K; Sakamoto Y; Tang W
Biomed Pharmacother; 2018 Mar; 99():921-930. PubMed ID: 29710492
[TBL] [Abstract][Full Text] [Related]
45. Radiosensitization by the combination of SR-2508 and paclitaxel in hypoxic human tumor cells in vitro.
Jin C; Bai L; Guo G
J Radiat Res; 2007 May; 48(3):179-85. PubMed ID: 17420623
[TBL] [Abstract][Full Text] [Related]
46. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
[TBL] [Abstract][Full Text] [Related]
47. Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27.
Asanuma F; Yamada Y; Kawamura E; Lee K; Kobayashi H; Yamada T; Suzuki T; Kubota T
Folia Microbiol (Praha); 1998; 43(5):473-4. PubMed ID: 9821299
[TBL] [Abstract][Full Text] [Related]
48. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
[TBL] [Abstract][Full Text] [Related]
49. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Wang C; Wei X; Shao G
Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
[TBL] [Abstract][Full Text] [Related]
50. Anticancer activity of new cationic arylthiophenes against hepatocellular carcinoma.
Al-Shun SA; El-Senduny FF; Ismail MA; El-Sayed WM; Badria FA; Youssef MM
Life Sci; 2021 Mar; 269():119028. PubMed ID: 33444618
[TBL] [Abstract][Full Text] [Related]
51. Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers.
Yi X; Lian X; Dong J; Wan Z; Xia C; Song X; Fu Y; Gong T; Zhang Z
Mol Pharm; 2015 Nov; 12(11):4085-98. PubMed ID: 26422373
[TBL] [Abstract][Full Text] [Related]
52. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
53. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
Tan J; Ye J; Song M; Zhou M; Hu Y
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
[TBL] [Abstract][Full Text] [Related]
54. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
55. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
[TBL] [Abstract][Full Text] [Related]
56. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
57. Combined effects of Cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo.
Yang Y; Lv QJ; Du QY; Yang BH; Lin RX; Wang SQ
World J Gastroenterol; 2005 Apr; 11(16):2491-6. PubMed ID: 15832424
[TBL] [Abstract][Full Text] [Related]
58. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines.
Gagandeep S; Novikoff PM; Ott M; Gupta S
Cancer Lett; 1999 Feb; 136(1):109-18. PubMed ID: 10211948
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
[TBL] [Abstract][Full Text] [Related]
60. Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab')
Jin C; Bai L; Lin L; Wang S; Yin X
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1076-1084. PubMed ID: 28776396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
